Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Androgens and antiandrogens.

H P G Schneider1

  • 1Department of Obstetrics Gynecology, University of Muenster, Von-Esmarch-Strasse 56, ZMBE, 48149 Muenster, Germany. hpg.schneider@uni-muenster.de

Annals of the New York Academy of Sciences
|December 4, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality of life in climacteric women.

Climacteric : the journal of the International Menopause Society·2017
Same author

Progesterone--promoter or inhibitor of breast cancer.

Climacteric : the journal of the International Menopause Society·2013
Same author

Assessment of health-related quality of life in menopause and aging.

Climacteric : the journal of the International Menopause Society·2008
Same author

Hormones and progeny of breast tumor cells.

Climacteric : the journal of the International Menopause Society·2006
Same author

IARC monographs program on carcinogenicity of combined hormonal contraceptives and menopausal therapy.

Climacteric : the journal of the International Menopause Society·2006
Same author

[Guidelines for hormone treatment of women in the menopausal transition and beyond: position statement by the Executive Committee of the International Menopause Society].

Lijecnicki vjesnik·2005

Androgen insufficiency in women, often overlooked, requires accurate testing and assessment alongside adequate estrogen levels. New progestins with antiandrogenic properties offer potential benefits in hormone replacement therapy without negating estrogen's positive effects.

Area of Science:

  • Endocrinology
  • Women's Health
  • Pharmacology

Background:

  • The role of androgens in women's health is under-recognized, with current assays lacking sensitivity for low ranges.
  • Androgens are crucial prohormones influencing diverse physiological and behavioral systems in women.
  • Androgen insufficiency can arise from age-related declines in adrenal and ovarian production, not solely menopause.

Purpose of the Study:

  • To review the assessment and clinical significance of androgens in women's health.
  • To discuss the diagnostic criteria for androgen insufficiency, emphasizing adequate estrogenization.
  • To explore the properties and therapeutic potential of novel progestins with antiandrogenic activity.

Main Methods:

  • Review of current literature on androgen assays and their limitations in women.

Related Experiment Videos

  • Analysis of clinical assessment methods for androgen production and availability, including specific hormone measurements.
  • Evaluation of the pharmacological profiles of new progestins, focusing on their antiandrogenic properties and potential side effects.

    • Main Results:

    • Accurate assessment of androgens in women can be achieved using measures like total testosterone (T) and sex-hormone binding globulin (SHBG), or dehydroepiandrosterone sulfate (DHEA-S) for adrenal androgens.
    • Androgen insufficiency diagnosis requires confirmation of adequate estrogenization to avoid misinterpretation.
    • New progestins (dienogest, drospirenone) exhibit antiandrogenic properties, potentially mitigating androgenic side effects and preserving beneficial estrogen effects.

    Conclusions:

    • Accurate and sensitive assays are needed for reliable androgen assessment in women.
    • Clinical diagnosis of androgen insufficiency must consider estrogen status and comprehensive assessment.
    • Novel progestins with antiandrogenic profiles present a promising alternative in hormone replacement therapy for women, balancing efficacy and safety.